BK polyomavirus RNA

BK polyomavirus RNA is not itself a canonical therapeutic target, receptor, or enzyme, but refers collectively to all RNA species transcribed from the BK polyomavirus genome during the viral life cycle. BK polyomavirus (BKPyV) is a small, non-enveloped DNA virus of about 5 kb that infects humans, establishing latency particularly in the kidneys[1][3]. Upon infection, the viral genome is transcribed to generate several early and late-region RNAs, which are then translated into regulatory proteins (large T antigen, small t antigen) and structural proteins (VP1, VP2, VP3, agnoprotein)[1][3]. These transcripts support viral replication, protein expression, and modulation of the host cell cycle, among other functions[1][2]. BK polyomavirus RNAs do not directly represent a molecular target recognized in pharmacology (such as a receptor, transporter, or enzyme), although the viral proteins encoded by these RNAs—especially the large T antigen—are established viral therapeutic targets and crucial to the viral life cycle[6]. Additionally, small RNAs derived from or targeting viral RNA have been explored for research and possible antiviral approaches, but the term "BK polyomavirus RNA" does not refer to a unique molecular entity suitable for classification as a therapeutic target[2][5]. Note: - The query appears to misunderstand the nature of a "target": "BK polyomavirus RNA" is not a single molecular target but a collection of transcribed RNAs. The canonical therapeutic targets are the viral proteins or functional domains they encode, not the aggregate of viral RNA molecules. - For structured information, use gene or protein names such as "Large T antigen (BK polyomavirus)" or "BK polyomavirus capsid protein VP1" instead, as those are valid therapeutic/diagnostic targets.

Other names

BKPyV viral RNABK polyomavirus transcriptomeBK virus RNA